share_log

Predictive Oncology to Report First Quarter 2024 Financial Results On Wednesday, May 15, 2024

Predictive Oncology to Report First Quarter 2024 Financial Results On Wednesday, May 15, 2024

預測腫瘤學將於2024年5月15日星期三公佈2024年第一季度財務業績
Predictive Oncology ·  05/10 00:00

Management to host conference call and webcast at 8:30am ET

管理層將在美國東部時間上午 8:30 主持電話會議和網絡直播

PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the first quarter ended March 31, 2024 before the markets open on Wednesday, May 15, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET.

匹茲堡,2024年5月10日(GLOBE NEWSWIRE)——Predictive Oncology Inc.(納斯達克股票代碼:POAI)是一家以科學爲導向的公司,利用其專有的人工智能和機器學習能力、龐大的腫瘤樣本生物庫、臨床實驗室改進修正案(CLIA)實驗室和良好生產規範(GMP)設施,以加快腫瘤藥物的發現並促進藥物開發。該公司今天宣佈,將在2024年3月31日之前公佈截至2024年3月31日的第一季度財務業績市場將於2024年5月15日星期三開盤。該公司將在美國東部時間上午 8:30 舉辦公司更新電話會議和網絡直播音頻。

Live Conference Call & Webcast:
Toll Free: 877-407-3982
International: 201-493-6780
Conference ID: 13746389
Call me: here
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1669074&tp_key=149e847466
電話會議直播和網絡直播:
免費電話: 877-407-3982
國際: 201-493-6780
會議編號: 13746389
給我打電話: 這裏
網絡直播: https://viavid.webcasts.com/starthere.jsp?ei=1669074&tp_key=149e847466


A replay of the webcast will be available in the Investors section of the Predictive Oncology website at https://investors.predictive-oncology.com/events-and-presentations.


網絡直播的重播將在預測腫瘤學網站的 “投資者” 欄目中播出,網址爲 https://investors.predictive-oncology.com/events-and-presentations

About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the Company's vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry's broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA.

關於預測腫瘤學
Predictive Oncology 在人工智能和機器學習的使用迅速增長方面處於前沿,以加快早期藥物發現並實現藥物開發,造福全球癌症患者。該公司經過科學驗證的人工智能平台PEDAL能夠以92%的準確率預測腫瘤樣本是否會對某種藥物化合物產生反應,從而可以更明智地選擇藥物/腫瘤類型的組合進行後續體外測試。Predictive Oncology 再加上公司龐大的生物庫,裏面有超過 150,000 個具有檢測能力的異源人類腫瘤樣本,爲其學術和行業合作伙伴提供了業內最廣泛的人工智能藥物發現解決方案之一,其全資擁有的 CLIA 實驗室和 GMP 設施進一步補充了這一點。預測腫瘤學總部位於賓夕法尼亞州匹茲堡。

Contact:
Predictive Oncology Inc.
Theresa Ferguson, Senior Director of Marketing
Phone: (630) 566-2003
tferguson@predictive-oncology.com

聯繫人:
預測腫瘤學公司
特蕾莎·弗格森,營銷高級董事
電話:(630) 566-2003
tferguson@predictive-oncology.com

Predictive Oncology Investor Relations
Tim McCarthy
LifeSci Advisors, LLC.
tim@lifesciadvisors.com

預測腫瘤學投資者關係
蒂姆·麥卡錫
LifeSci Advisors, LLC
tim@lifesciadvisors.com

Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "would," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading "Risk Factors" in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

前瞻性陳述:
本新聞稿中討論的某些事項包含前瞻性陳述。這些前瞻性陳述反映了我們當前對未來事件的預期和預測,並受有關我們的運營和投資的重大風險、不確定性和假設的影響。本新聞稿中有關我們的戰略、未來運營、未來財務狀況、未來收入和財務業績、預計成本、前景、管理層變動、管理計劃和目標的所有陳述,除歷史事實陳述外,均爲前瞻性陳述。“預期”、“相信”、“估計”、“期望”、“打算”、“可能”、“計劃”、“將”、“目標” 等詞語以及類似的表述旨在識別前瞻性陳述,儘管並非所有前瞻性陳述都包含這些識別詞。由於多種因素,包括我們在向美國證券交易委員會提交的文件中 “風險因素” 標題下討論的因素等,我們的實際未來表現可能與前瞻性陳述所設想的存在重大差異。除非法律明確要求,否則公司不承擔任何更新這些前瞻性陳述的意圖或義務。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論